These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

622 related articles for article (PubMed ID: 17709460)

  • 81. Mortality differences among hospitalized patients with community-acquired pneumonia in three world regions: results from the Community-Acquired Pneumonia Organization (CAPO) International Cohort Study.
    Arnold FW; Wiemken TL; Peyrani P; Ramirez JA; Brock GN;
    Respir Med; 2013 Jul; 107(7):1101-11. PubMed ID: 23660396
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Comparative Treatment Failure Rates of Respiratory Fluoroquinolones or β-Lactam + Macrolide Versus β-Lactam Alone in the Treatment for Community-Acquired Pneumonia in Adult Outpatients: An Analysis of a Nationally Representative Claims Database.
    Lee MG; Lee SH; Chang SS; Chan YL; Pang L; Hsu SM; Lee CC
    Medicine (Baltimore); 2015 Sep; 94(39):e1662. PubMed ID: 26426664
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Community-acquired pneumonia in Malaysian patients: addition of macrolide and the use of BTS "curb" index to assess severity.
    Loh LC
    Med J Malaysia; 2006 Mar; 61(1):128-30. PubMed ID: 16708753
    [No Abstract]   [Full Text] [Related]  

  • 84. Alveolar-arterial oxygen gradient, pneumonia severity index and outcomes in patients hospitalized with community acquired pneumonia.
    Moammar MQ; Azam HM; Blamoun AI; Rashid AO; Ismail M; Khan MA; DeBari VA
    Clin Exp Pharmacol Physiol; 2008 Sep; 35(9):1032-7. PubMed ID: 18518885
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Beta-Lactam Plus Macrolide for Patients Hospitalized With Community-Acquired Pneumonia: Difference Between Autumn and Spring.
    Kim Y; Jeon Y; Kwon KT; Bae S; Hwang S; Chang HH; Kim SW; Lee WK; Yang KH; Shin JH; Shim EK
    J Korean Med Sci; 2022 Nov; 37(45):e324. PubMed ID: 36413797
    [TBL] [Abstract][Full Text] [Related]  

  • 86. The etiology of community-acquired pneumonia in Australia: why penicillin plus doxycycline or a macrolide is the most appropriate therapy.
    Charles PG; Whitby M; Fuller AJ; Stirling R; Wright AA; Korman TM; Holmes PW; Christiansen KJ; Waterer GW; Pierce RJ; Mayall BC; Armstrong JG; Catton MG; Nimmo GR; Johnson B; Hooy M; Grayson ML;
    Clin Infect Dis; 2008 May; 46(10):1513-21. PubMed ID: 18419484
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Outcomes of Macrolide Deescalation in Severe Community-acquired Pneumonia.
    Hopkins TM; Juang P; Weaver K; Kollef MH; Betthauser KD
    Clin Ther; 2019 Dec; 41(12):2540-2548. PubMed ID: 31676040
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Empirical antibiotic treatment strategies for community-acquired pneumonia: a network meta-analysis.
    Xu LY; Wang CC; Peng XX; Jiao Y; Zhao CZ; Zhang L; Ma L
    J Glob Antimicrob Resist; 2022 Sep; 30():1-9. PubMed ID: 35643393
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Community-Acquired Pneumonia in Adults: Diagnosis and Management.
    Kaysin A; Viera AJ
    Am Fam Physician; 2016 Nov; 94(9):698-706. PubMed ID: 27929242
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Macrolides versus quinolones in Legionella pneumonia: results from the Community-Acquired Pneumonia Organization international study.
    Griffin AT; Peyrani P; Wiemken T; Arnold F
    Int J Tuberc Lung Dis; 2010 Apr; 14(4):495-9. PubMed ID: 20202309
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study.
    File TM; Mandell LA; Tillotson G; Kostov K; Georgiev O
    J Antimicrob Chemother; 2007 Jul; 60(1):112-20. PubMed ID: 17537866
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Oral gemifloxacin versus sequential therapy with intravenous ceftriaxone/oral cefuroxime with or without a macrolide in the treatment of patients hospitalized with community-acquired pneumonia: a randomized, open-label, multicenter study of clinical efficacy and tolerability.
    Lode H; File TM; Mandell L; Ball P; Pypstra R; Thomas M;
    Clin Ther; 2002 Nov; 24(11):1915-36. PubMed ID: 12501883
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Doxycycline vs. macrolides in combination with a β-lactam antibiotic for the treatment of community-acquired pneumonia in inpatients.
    Aldhahri RK; Gabb SG; Shoaib OA; Almadani RM; Eljaaly K; Thabit AK
    Eur J Med Res; 2022 Dec; 27(1):279. PubMed ID: 36482485
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Doxycycline vs. levofloxacin in the treatment of community-acquired pneumonia.
    Mokabberi R; Haftbaradaran A; Ravakhah K
    J Clin Pharm Ther; 2010 Apr; 35(2):195-200. PubMed ID: 20456738
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Ceftriaxone versus ceftriaxone plus a macrolide for community-acquired pneumonia in hospitalized patients with HIV/AIDS: a randomized controlled trial.
    Figueiredo-Mello C; Naucler P; Negra MD; Levin AS
    Clin Microbiol Infect; 2018 Feb; 24(2):146-151. PubMed ID: 28648859
    [TBL] [Abstract][Full Text] [Related]  

  • 96. In non-ICU suspected CAP, β-lactam was noninferior to β-lactam-macrolide or fluoroquinolone for 90-d mortality.
    Fekete T
    Ann Intern Med; 2015 Sep; 163(6):JC5. PubMed ID: 26370032
    [No Abstract]   [Full Text] [Related]  

  • 97. Prescribing trends and revisit rates following a pharmacist-driven protocol change for community-acquired pneumonia in an emergency department.
    Zimmerman DE; Covvey JR; Nemecek BD; Guarascio AJ; Wilson L; Freedy HR; Yassin MH
    Int J Pharm Pract; 2019 Jun; 27(3):279-285. PubMed ID: 30536468
    [TBL] [Abstract][Full Text] [Related]  

  • 98. How Antibiotics Should be Prescribed to Hospitalized Elderly Patients with Community-Acquired Pneumonia.
    Arnold FW
    Drugs Aging; 2017 Jan; 34(1):13-20. PubMed ID: 27928779
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Effect of a 3-step critical pathway to reduce duration of intravenous antibiotic therapy and length of stay in community-acquired pneumonia: a randomized controlled trial.
    Carratalà J; Garcia-Vidal C; Ortega L; Fernández-Sabé N; Clemente M; Albero G; López M; Castellsagué X; Dorca J; Verdaguer R; Martínez-Montauti J; Manresa F; Gudiol F
    Arch Intern Med; 2012 Jun; 172(12):922-8. PubMed ID: 22732747
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Ertapenem as initial antimicrobial monotherapy for patients with chronic obstructive pulmonary disease hospitalized with typical community-acquired pneumonia.
    Friedland IR; McCarroll KA; DiNubile MJ; Woods GL
    Pulm Pharmacol Ther; 2004; 17(4):199-203. PubMed ID: 15219264
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.